Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (501)	1/29/2004 4:34:54 PM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

SEPR Hasn't entirely closed its March 8 2002 downgap (gap was from 44.05 to 19.15 and the H on Sep.17,2003 was 32.79) The thing to watch now is the FDA's final action on Estorra. Last week SEPR's CFO said he believes that the drug is "still on track" for an approval in time for a midyear launch. He said that the company is expecting an approval letter by Feb.29 Hope is that Estorra won't run into similar problems as Soltara did in 2002. The FDA didn't give any reason why it didn't make a ruling on Estorra as was expected in December and there seems to be no reason to think that there is a problem with the drug. SEPR tested its nearest support today at the 26.80 level.If that doesn't hold the next support is at 25.65 and it seems to have very good support at the 24 level. The nearest resistance is at the January 21 H of 29.14 and then the October 8 H at 31.31 bigcharts.marketwatch.com On good news from the FDA on Estorra it should have no problems on closing above its September H of 32.79 and to fully close the aforementioned March 2002 downgap.<g> bigcharts.marketwatch.com Bernard